Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Synonyms
Levetiracetam
Levetiracetamum
Levetiracetame
Lévétiracetam
Brand Names
Apo-levetiracetam
Levetiracetam extended-release
Roweepra
Pro-levetiracetam - 500
Ach-levetiracetam
Pro-levetiracetam - 750
Levetiracetam Ratiopharm
Levetiracetam Extended-Release
Levetiracetam 250 mg
Levertiracetam
Levetiracetam Levetiracetam
M-levetiracetam
Nu-levetiracetam
LEVETIRACETAM solution
Auro-levetiracetam
Levetiracetam in Sodium Chloride
Pharma-levetiracetam
Nra-levetiracetam
Levetiracetam 1000 mg
Levetiracetam Micro
Keppra XR
Teva-levetiracetam
PHL-levetiracetam
Jamp Levetiracetam Tablets
Matever
Levetiracetam 750 mg
Levetiracetam Actavis
PMS-levetiracetam
Keppra
Levetiracetam Extended-release
Nat-levetiracetam
Elepsia XR 1000 mg
Elepsia XR 1500 mg
Van-levetiracetam
Ag-levetiracetam
Levetiracetam Injection USP
Levetiracetam Teva
Spritam
Pdp-levetiracetam
Jamp-levetiracetam
Ava-levetiracetam
Elepsia XR
Roweepra XR
Sandoz Levetiracetam
Bio-levetiracetam
Pro-levetiracetam - 250
LEVETIRACETAM Extended-release
Levetiracetam ER
Priva-levetiracetam
Levetiractam
Mint-levetiracetam
Novo-levetiracetam
Levetiracetam Extended Release
Levetiracetam Accord
Riva-levetiracetam
Levetiracetam Hospira
Ran-levetiracetam
Levetiracetam Actavis Group
Tva-levetiracetam
Levetiracetam
Dom-levetiracetam
Abbott-levetiracetam
Levetiracetam Sun
Mint-levetiracetam Solution
Torrent-levetiracetam
Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Categories
Acetamides
Amides
Anticonvulsants
Central Nervous System Agents
Central Nervous System Depressants
Decreased Central Nervous System Disorganized Electrical Activity
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682